Cargando…
Bone Strength/Bone Mass Discrepancy in Glucocorticoid‐Treated Adult Mice
Glucocorticoids increase bone fragility in patients in a manner that is underestimated by bone mass measurement. This study aimed to determine if the adult mouse could model this bone strength/bone mass discrepancy. Forty‐two 13‐week‐old BALB/cJ mice were randomized into vehicle and glucocorticoid g...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990143/ https://www.ncbi.nlm.nih.gov/pubmed/33778319 http://dx.doi.org/10.1002/jbm4.10443 |
_version_ | 1783669020814213120 |
---|---|
author | Dubrovsky, Alanna M. Nyman, Jeffrey S. Uppuganti, Sasidhar Chmiel, Kenneth J. Kimmel, Donald B. Lane, Nancy E |
author_facet | Dubrovsky, Alanna M. Nyman, Jeffrey S. Uppuganti, Sasidhar Chmiel, Kenneth J. Kimmel, Donald B. Lane, Nancy E |
author_sort | Dubrovsky, Alanna M. |
collection | PubMed |
description | Glucocorticoids increase bone fragility in patients in a manner that is underestimated by bone mass measurement. This study aimed to determine if the adult mouse could model this bone strength/bone mass discrepancy. Forty‐two 13‐week‐old BALB/cJ mice were randomized into vehicle and glucocorticoid groups, implanted with vehicle or 6‐methylprednisolone pellets, and necropsied after 60 and 120 days. Bone strength and bone mass/microarchitecture were assessed at the right central femur (CF; cortical‐bone–rich) and sixth lumbar vertebral body (LVB6; trabecular‐bone–rich). Bound water (BW) of the whole right femur was analyzed by proton‐nuclear magnetic resonance ((1)H‐NMR) relaxometry. Data were analyzed by two‐factor ANOVA with time (day 60 and day 120) and treatment (vehicle and glucocorticoid) as main effects for all data. Significant interactions were further analyzed with a Tukey's post hoc test. Most bone strength measures in the CF were lower in the glucocorticoid group, regardless of the duration of treatment, with no time × treatment interaction. However, bone mass measures in the CF showed a significant time × treatment interaction (p = 0.0001). Bone strength measures in LVB6 showed a time × treatment interaction (p < 0.02) such that LVB6 strength was lower after 120 days of glucocorticoids compared with 120 days of vehicle treatment. Whole‐femur–BW was lower with both glucocorticoid treatment (p = 0.0001) and time (p < 0.02), with a significant time × treatment interaction (p = 0.005). Glucocorticoid treatment of male BALB/cJ mice resulted in the lowering of bone strength in both cortical and trabecular bone that either appeared earlier or was greater than the treatment‐related changes in bone mass/microarchitecture. The adult mouse may be a good model for investigating the bone strength/mass discrepancy observed in glucocorticoid‐treated patients. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research. |
format | Online Article Text |
id | pubmed-7990143 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79901432021-03-25 Bone Strength/Bone Mass Discrepancy in Glucocorticoid‐Treated Adult Mice Dubrovsky, Alanna M. Nyman, Jeffrey S. Uppuganti, Sasidhar Chmiel, Kenneth J. Kimmel, Donald B. Lane, Nancy E JBMR Plus Original Articles Glucocorticoids increase bone fragility in patients in a manner that is underestimated by bone mass measurement. This study aimed to determine if the adult mouse could model this bone strength/bone mass discrepancy. Forty‐two 13‐week‐old BALB/cJ mice were randomized into vehicle and glucocorticoid groups, implanted with vehicle or 6‐methylprednisolone pellets, and necropsied after 60 and 120 days. Bone strength and bone mass/microarchitecture were assessed at the right central femur (CF; cortical‐bone–rich) and sixth lumbar vertebral body (LVB6; trabecular‐bone–rich). Bound water (BW) of the whole right femur was analyzed by proton‐nuclear magnetic resonance ((1)H‐NMR) relaxometry. Data were analyzed by two‐factor ANOVA with time (day 60 and day 120) and treatment (vehicle and glucocorticoid) as main effects for all data. Significant interactions were further analyzed with a Tukey's post hoc test. Most bone strength measures in the CF were lower in the glucocorticoid group, regardless of the duration of treatment, with no time × treatment interaction. However, bone mass measures in the CF showed a significant time × treatment interaction (p = 0.0001). Bone strength measures in LVB6 showed a time × treatment interaction (p < 0.02) such that LVB6 strength was lower after 120 days of glucocorticoids compared with 120 days of vehicle treatment. Whole‐femur–BW was lower with both glucocorticoid treatment (p = 0.0001) and time (p < 0.02), with a significant time × treatment interaction (p = 0.005). Glucocorticoid treatment of male BALB/cJ mice resulted in the lowering of bone strength in both cortical and trabecular bone that either appeared earlier or was greater than the treatment‐related changes in bone mass/microarchitecture. The adult mouse may be a good model for investigating the bone strength/mass discrepancy observed in glucocorticoid‐treated patients. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research. John Wiley & Sons, Inc. 2020-12-21 /pmc/articles/PMC7990143/ /pubmed/33778319 http://dx.doi.org/10.1002/jbm4.10443 Text en © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Dubrovsky, Alanna M. Nyman, Jeffrey S. Uppuganti, Sasidhar Chmiel, Kenneth J. Kimmel, Donald B. Lane, Nancy E Bone Strength/Bone Mass Discrepancy in Glucocorticoid‐Treated Adult Mice |
title | Bone Strength/Bone Mass Discrepancy in Glucocorticoid‐Treated Adult Mice |
title_full | Bone Strength/Bone Mass Discrepancy in Glucocorticoid‐Treated Adult Mice |
title_fullStr | Bone Strength/Bone Mass Discrepancy in Glucocorticoid‐Treated Adult Mice |
title_full_unstemmed | Bone Strength/Bone Mass Discrepancy in Glucocorticoid‐Treated Adult Mice |
title_short | Bone Strength/Bone Mass Discrepancy in Glucocorticoid‐Treated Adult Mice |
title_sort | bone strength/bone mass discrepancy in glucocorticoid‐treated adult mice |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990143/ https://www.ncbi.nlm.nih.gov/pubmed/33778319 http://dx.doi.org/10.1002/jbm4.10443 |
work_keys_str_mv | AT dubrovskyalannam bonestrengthbonemassdiscrepancyinglucocorticoidtreatedadultmice AT nymanjeffreys bonestrengthbonemassdiscrepancyinglucocorticoidtreatedadultmice AT uppugantisasidhar bonestrengthbonemassdiscrepancyinglucocorticoidtreatedadultmice AT chmielkennethj bonestrengthbonemassdiscrepancyinglucocorticoidtreatedadultmice AT kimmeldonaldb bonestrengthbonemassdiscrepancyinglucocorticoidtreatedadultmice AT lanenancye bonestrengthbonemassdiscrepancyinglucocorticoidtreatedadultmice |